QNRX

Quoin Pharmaceuticals, Ltd. operates as a specialty pharmaceutical company focused on developing and commercializing therapeutic products for rare and orphan diseases. Headquartered in Ashburn, Virginia, the company concentrates primarily on dermatological conditions with significant unmet medical needs. Quoin's lead product candidate, QRX003, is a topical lotion being developed for the treatment of Netherton Syndrome, a rare genetic skin disorder, and is also being evaluated for Peeling Skin Syndrome. The company's portfolio includes QRX004, a topical lotion for treatment of epidermolysis bullosa, a group of rare genetic connective tissue disorders. Quoin leverages a strategy of in-licensing and developing de-risked therapeutic candidates that have previously demonstrated clinical proof-of-concept. The company trades on the Nasdaq Capital Market and maintains a focused pipeline approach targeting rare diseases with limited treatment options. In recent developments, Quoin has advanced its clinical programs through various trial phases while managing its capital resources through equity financing activities. The company operates with a lean organizational structure typical of clinical-stage biopharmaceutical firms, prioritizing research and development expenditures over commercial infrastructure. Quoin's business model centers on achieving regulatory approvals for its product candidates and potentially partnering for commercialization or building selective commercial capabilities in rare disease markets.